Literature DB >> 656304

Monocytes and macrophages in malignant melanoma. III. Reduction of nitroblue tetrazolium by peripheral blood monocytes.

D W Hedley, G A Currie.   

Abstract

Peripheral-blood monocytes from normal individuals and from patients with malignant melanoma reduce nitroblue tetrazolium (NBT). A quantitative assay for dye reduction was applied to 25 healthy donors and 31 patients with malignant melanoma. NBT reduction expressed as dye reduction per monocyte was significantly impaired in patients with disseminated disease, and they responded poorly to a phagocytic stimulus. Monocytes from patients with micrometastatic disease, however, showed normal resting NBT reduction but, following exposure to a suspension of latex-polystyrene, showed significantly greater NBT reduction than those from normal individuals. Since NBT reduction is an indirect measure of intracellular hexose-monophosphate-shunt activity we conclude that the monocytes from patients with minimal disease are in some way activated.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 656304      PMCID: PMC2009614          DOI: 10.1038/bjc.1978.113

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Activation of human blood monocytes by products of sensitized lymphocytes.

Authors:  R E Rocklin; C T Winston; J R David
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

2.  Altered expression of human monocyte Fc receptors in malignant disease.

Authors:  J Rhodes
Journal:  Nature       Date:  1977-01-20       Impact factor: 49.962

3.  Functional abnormalities of neutrophils in cancer patients : inefficient phagocytosis and reverse endocytosis.

Authors:  P Henon; I Gerota; S Palacios
Journal:  Biomedicine       Date:  1977-10

4.  The nitroblue tetrazolium test in lymphoma.

Authors:  E M Silverman; R E Reed
Journal:  Am J Clin Pathol       Date:  1973-08       Impact factor: 2.493

5.  Infection and nitroblue-tetrazolium reduction by neutrophils. A diagnostic acid.

Authors:  B H Park; S M Fikrig; E M Smithwick
Journal:  Lancet       Date:  1968-09-07       Impact factor: 79.321

6.  Nitroblue tetrazolium dye reduction by peripheral leukocytes from rheumatoid arthritis and systemic lupus erythematosus patients measured by a histochemical and spectrophotometric method.

Authors:  M E Wenger; G G Bole
Journal:  J Lab Clin Med       Date:  1973-09

7.  Abnormal monocyte chemotactic response in cancer patients.

Authors:  D A Boetcher; E J Leonard
Journal:  J Natl Cancer Inst       Date:  1974-04       Impact factor: 13.506

8.  Monocytes and macrophages in malignant melanoma. I. Peripheral blood macrophage precursors.

Authors:  G A Currie; D W Hedley
Journal:  Br J Cancer       Date:  1977-07       Impact factor: 7.640

9.  The mechanism of the entry of dye into neutrophils in the nitroblue tetrazolium (NBT) test.

Authors:  A W Segal; A J Levi
Journal:  Clin Sci Mol Med       Date:  1973-12

10.  Human monocyte glucose metabolism in lymphoma.

Authors:  G W King; A F Lobuglio; A L Sagone
Journal:  J Lab Clin Med       Date:  1977-02
View more
  9 in total

1.  Macrophage function in chronic experimental alcoholism. I. Modulation of surface receptors and phagocytosis.

Authors:  O Bagasra; A Howeedy; A Kajdacsy-Balla
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

Review 2.  Disordered function of mononuclear phagocytes in malignant disease.

Authors:  R J Sokol; G Hudson
Journal:  J Clin Pathol       Date:  1983-03       Impact factor: 3.411

3.  A quantitative and qualitative study of blood monocytes in patients with bronchogenic carcinoma.

Authors:  H Nielsen; J Bennedsen; S O Larsen; P Dombernowsky; K Viskum
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

4.  Monocyte function in cirrhosis.

Authors:  G Holdstock; B Leslie; S Hill; A Tanner; R Wright
Journal:  J Clin Pathol       Date:  1982-09       Impact factor: 3.411

5.  Decrease in the phagocytic activity of peripheral monocytes in patients treated with human interferon-alpha.

Authors:  S Einhorn; C Jarstrand
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

6.  Activation of human monocytes for nitroblue tetrazolium reduction and the suppression of lymphocyte response to mitogens.

Authors:  M Zembala; E M Lemmel; W Uracz
Journal:  Clin Exp Immunol       Date:  1980-08       Impact factor: 4.330

7.  Effect of autologous and homologous serum and circulating immune complexes on monocyte functions of patients with solid tumours.

Authors:  A Celada; T Aguado; P H Lambert; A Cruchaud
Journal:  Clin Exp Immunol       Date:  1980-08       Impact factor: 4.330

8.  "Activated" monocytes in gastric cancer patients. I. Increased Fc receptor expression, antibody-dependent cellular cytotoxicity and NBT reduction.

Authors:  W Uracz; A Pituch-Noworolska; M Zembala; T Popiela; A Czupryna
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

9.  Monocytes and macrophages in malignant melanoma IV. Effects of C. parvum on monocyte function.

Authors:  D W Hedley; R E Nyholm; G A Currie
Journal:  Br J Cancer       Date:  1979-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.